An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro

Circulation

Volumn 103, Issue 2, 2001, Pages 276-283

  Aikawa, Masanori ^a,c   Rabkin, Elena ^a   Sugiyama, Seigo ^a   Voglic, Sami J ^a   Fukumoto, Yoshihiro ^a   Furukawa, Yutaka ^a   Shiomi, Masashi ^b   Schoen, Frederick J ^a   Libby, Peter ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b KOBE UNIVERSITY   (Japan)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Atherosclerosis; Hypercholesterolemia; Inflammation; Metalloproteinas es; Thrombosis

Indexed keywords

CERIVASTATIN; CHOLESTEROL; GELATINASE A; GELATINASE B; HISTONE; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; MESSENGER RNA; THROMBOPLASTIN;

ACUTE HEART FAILURE; ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROMA; ATHEROSCLEROTIC PLAQUE; CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; IN SITU HYBRIDIZATION; MACROPHAGE; MACROPHAGE ACTIVATION; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RABBIT; THROMBOGENICITY; TREATMENT OUTCOME;

EID: 0035895319     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.103.2.276     Document Type: Article

References (40)

1. Molecular bases of the acute coronary syndromes
2. Coronary plaque disruption
3. Macrophage infiltration in acute coronary syndromes: Implications for plaque rupture
4. Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization
5. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques
6. Interstitial collagenase (MMP-1) expression in human carotid atherosclerosis
7. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque
8. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: Induction of collagenase, stromelysin, and tissue factor
9. Macrophages and atherosclerotic plaque stability
10. Tissue factor in the pathogenesis of atherosclerosis
11. Endothelial cells in inflammation
12. Colony-stimulating factor-induced monocyte survival and differentiation into macrophages in serum-free cultures
13. Cell proliferation in human coronary arteries
14. Macrophage and smooth muscle cell proliferation in atherosclerotic lesions of WHHL and comparably hypercholesterolemic fat-fed rabbits
15. Active proliferation of different cell types, including lymphocytes, in human atherosclerotic plaques
16. The molecular control of cell division, differentiation commitment and maturation in haemopoietic cells
17. Lysophosphatidylcholine potentiates the mitogenic activity of modified LDL for human monocyte-derived macrophages
18. Oxidized LDL can induce macrophage survival, DNA synthesis, and enhanced proliferative response to CSF-1 and GM-CSF
19. Lipid lowering and plaque regression: New insights into prevention of plaque disruption and clinical events in coronary disease
20. New insights into plaque stabilisation by lipid lowering
21. The evolving role of statins in the management of atherosclerosis
22. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: A potential mechanism of lesion stabilization
23. Dietary lipid lowering reduces tissue factor expression in rabbit atheroma
24. Lipid lowering promotes accumulation of mature smooth muscle cells expressing smooth muscle myosin heavy chain isoforms in rabbit atheroma
25. Low-density lipoprotein-independent effects of statins
26. Preclinical review of cerivastatin sodium: A step forward in HMG-CoA reductase inhibition
27. Effect of cerivastatin sodium, a new inhibitor of HMG-CoA reductase, on plasma lipid levels, progression of atherosclerosis, and the lesional composition in the plaques of WHHL rabbits
28. Liver regeneration: A comparison of in situ hybridization for histone mRNA with bromodeoxyuridine labeling for the detection of S-phase cells
29. Distribution of cell replication and apoptosis in atherosclerotic plaques of cholesterol-fed rabbits
30. GM-CSF and M-CSF expression is associated with macrophage proliferation in progressing and regressing rabbit atheromatous lesions
31. A rapid method to determine proliferation patterns of normal and malignant tissues by H3 mRNA in situ hybridization
32. Regulation of human histone gene expression: Kinetics of accumulation and changes in the rate of synthesis and in the half-lives of individual histone mRNAs during the HeLa cell cycle
33. Effect of the new HMG-CoA reductase inhibitor cerivastatin (BAY W 6228) on migration, proliferation and cholesterol synthesis in arterial myocytes
34. Suppression of neointimal thickening by a newly developed HMG-CoA reductase inhibitor, BAYw6228, and its inhibitory effect on vascular smooth muscle cell growth
35. Preclinical and clinical pharmacology of cerivastatin
36. Pharmacodynamics, safety, tolerability, and pharmacokinetics of the 0.8-mg dose of cerivastatin in patients with primary hypercholesterolemia
37. HMG-CoA reductase inhibitors suppress macrophage growth induced by oxidized low density lipoprotein
38. 3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture
39. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages
40. Vastatins inhibit tissue factor in cultured human macrophages: A novel mechanism of protection against atherothrombosis